Recent advancements in the treatment of chronic myelogenous leukemia

Michael E. O'Dwyer; Michael J. Mauro; Brian J. Druker

doi:10.1146/annurev.med.53.082901.103853

Recent advancements in the treatment of chronic myelogenous leukemia

Michael E. O'Dwyer, Michael J. Mauro, Brian J. Druker

Knight Cancer Institute

Research output: Contribution to journal › Review article › peer-review

58 Scopus citations

Abstract

Chronic myelogenous leukemia (CML) is a clonal hematopoetic stem cell disorder characterized by the Philadelphia chromosome and resultant production of the constitutively activated Bcr-Abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem cell transplantation, with stem cell transplantation being the only curative therapy. Through rational drug development, STI571, a Bcr-Abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product targeted therapy, offering new hope for expanded treatment options for patients with CML.

Original language	English (US)
Pages (from-to)	369-381
Number of pages	13
Journal	Annual review of medicine
Volume	53
DOIs	https://doi.org/10.1146/annurev.med.53.082901.103853
State	Published - 2002

Keywords

Bcr-Abl
CML
STI571
Tyrosine kinase
Tyrosine kinase inhibitor

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1146/annurev.med.53.082901.103853

Cite this

@article{1dfc98266983493fba7c461be95fcd68,

title = "Recent advancements in the treatment of chronic myelogenous leukemia",

abstract = "Chronic myelogenous leukemia (CML) is a clonal hematopoetic stem cell disorder characterized by the Philadelphia chromosome and resultant production of the constitutively activated Bcr-Abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem cell transplantation, with stem cell transplantation being the only curative therapy. Through rational drug development, STI571, a Bcr-Abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product targeted therapy, offering new hope for expanded treatment options for patients with CML.",

keywords = "Bcr-Abl, CML, STI571, Tyrosine kinase, Tyrosine kinase inhibitor",

author = "O'Dwyer, {Michael E.} and Mauro, {Michael J.} and Druker, {Brian J.}",

year = "2002",

doi = "10.1146/annurev.med.53.082901.103853",

language = "English (US)",

volume = "53",

pages = "369--381",

journal = "Annual review of medicine",

issn = "0066-4219",

publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Recent advancements in the treatment of chronic myelogenous leukemia

AU - O'Dwyer, Michael E.

AU - Mauro, Michael J.

AU - Druker, Brian J.

PY - 2002

Y1 - 2002

N2 - Chronic myelogenous leukemia (CML) is a clonal hematopoetic stem cell disorder characterized by the Philadelphia chromosome and resultant production of the constitutively activated Bcr-Abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem cell transplantation, with stem cell transplantation being the only curative therapy. Through rational drug development, STI571, a Bcr-Abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product targeted therapy, offering new hope for expanded treatment options for patients with CML.

AB - Chronic myelogenous leukemia (CML) is a clonal hematopoetic stem cell disorder characterized by the Philadelphia chromosome and resultant production of the constitutively activated Bcr-Abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem cell transplantation, with stem cell transplantation being the only curative therapy. Through rational drug development, STI571, a Bcr-Abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product targeted therapy, offering new hope for expanded treatment options for patients with CML.

KW - Bcr-Abl

KW - CML

KW - STI571

KW - Tyrosine kinase

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0036179862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036179862&partnerID=8YFLogxK

U2 - 10.1146/annurev.med.53.082901.103853

DO - 10.1146/annurev.med.53.082901.103853

M3 - Review article

C2 - 11818480

AN - SCOPUS:0036179862

SN - 0066-4219

VL - 53

SP - 369

EP - 381

JO - Annual review of medicine

JF - Annual review of medicine

ER -

Recent advancements in the treatment of chronic myelogenous leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this